Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OncoSec Medical Inc ONCSQ

Healthcare Biotechnology
OncoSec Medical Incorporated is a late-stage immuno-oncology company. The Company is focused on designing, developing and commercializing intra-tumoral DNA-based therapeutics delivered by electroporation (EP) to stimulate and augment anti-tumor immune responses for the treatment of cancers. Its core technology, ImmunoPulse, is a drug-device therapeutic modality platform comprised of an OncoSec... see more

Recent & Breaking News (GREY:ONCSQ)

OncoSec Promotes Sheela Mohan-Peterson to Chief Legal and Compliance Officer

PR Newswire August 24, 2015

OncoSec Announces First Patient Enrolled in Phase II Clinical Trial Evaluating Combination of ImmunoPulse(TM) IL-12 and Anti-PD-1 Treatment

PR Newswire August 18, 2015

OncoSec to Webcast Annual Meeting of Stockholders

PR Newswire July 23, 2015

OTC Markets Group Announces Second Quarter 2015 Index Performance and Rebalancing

PR Newswire July 16, 2015

OncoSec Medical to Participate in Webcast on Advances in Cancer Immunotherapy

PR Newswire July 14, 2015

OncoSec Medical Inc. (Nasdaq: ONCS) to Ring The Nasdaq Stock Market Opening Bell

GlobeNewswire July 6, 2015

OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development

PR Newswire July 6, 2015

OncoSec Medical to Ring The Nasdaq Stock Market Opening Bell

PR Newswire July 1, 2015

OncoSec Medical Appoints Richard B. Slansky as Chief Financial Officer

PR Newswire June 25, 2015

OncoSec Medical Issues Annual Letter To Shareholders

PR Newswire June 17, 2015

OncoSec Medical Enrolls First Patient in Squamous Cell Carcinoma of the Head and Neck Phase II Clinical Trial

PR Newswire June 16, 2015

OncoSec Medical Set to Join Russell Microcap Index

PR Newswire June 15, 2015

OncoSec Medical Announces Nine Months Results for Fiscal Year End 2015

PR Newswire June 9, 2015

OncoSec Medical Closes $13.6 Million Registered Direct Offering

PR Newswire June 8, 2015

OncoSec Medical to Present at the BIO International Convention

PR Newswire June 4, 2015

OncoSec Medical Announces $13.6 Million Registered Direct Offering

PR Newswire June 3, 2015

OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma

PR Newswire June 1, 2015

OncoSec Medical Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market

PR Newswire May 14, 2015

Vista Partners Publishes May 2015 Macroeconomic & Investment Newsletter

Marketwired May 13, 2015

Robert H. Pierce, MD, Chief Scientific Officer of OncoSec Medical, Invited to Present at 11th Annual PEGS Conference in Boston

PR Newswire May 7, 2015